Helix Acquisition Corp. II Cl A (HLXB)

$10.49 +0.14 (1.35%)
Market Cap 190.44M
Revenue (ttm) 0.00
Net Income (ttm) -41,692.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 100
Avg Vol 10,912
Day's Range N/A - N/A
Shares Out 18.40M
Stochastic %K 25%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Helix Acquisition Corp. II focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Boston, Massachusetts.

Industry: Shell Companies
Sector: Financial Services
Phone: 857-702-0370
Address:
200 Clarendon Street, 52nd Floor, Boston, United States
javarich
javarich Jul. 4 at 11:53 AM
$BBIO $HLXB $RARE $MREO $BBOT Working to hard this morning. If you’re in here then you need to be in the spac spinoff o $BBOT this is the oncology division. https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-bbot-helix-124900685.html BridgeBio Oncology Therapeutics (BBOT) is directly connected to BridgeBio Pharma (BBIO) and Helix Acquisition Corp. II (HLXB). Here’s how they’re linked: Buy Helix now or don’t we get the worm late birds. The team is just too good to fail. 10x is all we do… ✅ Bottom Line • BridgeBio Pharma launched BBOT as part of its “hub-and-spoke” model to focus and accelerate oncology innovation. • Helix Acquisition Corp. II (HLXB) serves as the SPAC vehicle to take BBOT public, merging in Q3 2025 under the BBOT ticker. • Post-transaction, BBOT will be well-funded with ~$550M to advance its RAS/PI3K-targeted oncology programs.
0 · Reply
RonIsWrong
RonIsWrong Jun. 12 at 6:55 PM
$BBIO $HLXB BridgeBio Oncology Therapeutics (BBOT) Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types Data show that BBO-10203 covalently and specifically binds to the RAS-binding domain of PI3Kα, breaking its interaction with H-, N-, and KRAS and preventing them from activating PI3Kα In preclinical models, BBO-10203 treatment led to significant tumor growth inhibition across multiple tumor types, and demonstrated enhanced efficacy when combined with other anti-tumor agents, without inducing hyperglycemia BBO-10203 is currently being evaluated in a Phase 1 study in patients with HR+/HER2- or HER2+ BRCA, KRAS mutant colorectal cancer (CRC), and KRAS mutant non-small cell lung cancer (NSCLC)
0 · Reply
Jblack500
Jblack500 Mar. 31 at 10:27 PM
$HLXB It woke up
0 · Reply
Jblack500
Jblack500 Mar. 13 at 3:46 AM
$HLXB you aren't too bright. The guy you mentioned below has absolutely zero to do with this. He had a totally different company. So the people below have no relevance whatsoever
0 · Reply
dia_may
dia_may Mar. 1 at 2:33 PM
$HLXB $IBB $XBI $BBIO STFU quit lying
2 · Reply
dia_may
dia_may Mar. 1 at 2:32 PM
$HLXB LFG 🗣️🗣️🗣️
0 · Reply
dia_may
dia_may Mar. 1 at 2:32 PM
$HLXB get it to pennies
0 · Reply
dia_may
dia_may Mar. 1 at 2:32 PM
$HLXB tank
0 · Reply
dia_may
dia_may Mar. 1 at 2:31 PM
$HLXB tank this shit thank Irina & Steve Goss of Rockford, Michigan
0 · Reply
Jblack500
Jblack500 Feb. 28 at 6:58 PM
$HLXB $IBB $XBI $BBIO 11 watchers...early bird gets the worm
0 · Reply
Latest News on HLXB
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

Feb 28, 2025, 7:49 AM EST - 4 months ago

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Feb 14, 2024, 7:30 AM EST - 1 year ago

Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

javarich
javarich Jul. 4 at 11:53 AM
$BBIO $HLXB $RARE $MREO $BBOT Working to hard this morning. If you’re in here then you need to be in the spac spinoff o $BBOT this is the oncology division. https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-bbot-helix-124900685.html BridgeBio Oncology Therapeutics (BBOT) is directly connected to BridgeBio Pharma (BBIO) and Helix Acquisition Corp. II (HLXB). Here’s how they’re linked: Buy Helix now or don’t we get the worm late birds. The team is just too good to fail. 10x is all we do… ✅ Bottom Line • BridgeBio Pharma launched BBOT as part of its “hub-and-spoke” model to focus and accelerate oncology innovation. • Helix Acquisition Corp. II (HLXB) serves as the SPAC vehicle to take BBOT public, merging in Q3 2025 under the BBOT ticker. • Post-transaction, BBOT will be well-funded with ~$550M to advance its RAS/PI3K-targeted oncology programs.
0 · Reply
RonIsWrong
RonIsWrong Jun. 12 at 6:55 PM
$BBIO $HLXB BridgeBio Oncology Therapeutics (BBOT) Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types Data show that BBO-10203 covalently and specifically binds to the RAS-binding domain of PI3Kα, breaking its interaction with H-, N-, and KRAS and preventing them from activating PI3Kα In preclinical models, BBO-10203 treatment led to significant tumor growth inhibition across multiple tumor types, and demonstrated enhanced efficacy when combined with other anti-tumor agents, without inducing hyperglycemia BBO-10203 is currently being evaluated in a Phase 1 study in patients with HR+/HER2- or HER2+ BRCA, KRAS mutant colorectal cancer (CRC), and KRAS mutant non-small cell lung cancer (NSCLC)
0 · Reply
Jblack500
Jblack500 Mar. 31 at 10:27 PM
$HLXB It woke up
0 · Reply
Jblack500
Jblack500 Mar. 13 at 3:46 AM
$HLXB you aren't too bright. The guy you mentioned below has absolutely zero to do with this. He had a totally different company. So the people below have no relevance whatsoever
0 · Reply
dia_may
dia_may Mar. 1 at 2:33 PM
$HLXB $IBB $XBI $BBIO STFU quit lying
2 · Reply
dia_may
dia_may Mar. 1 at 2:32 PM
$HLXB LFG 🗣️🗣️🗣️
0 · Reply
dia_may
dia_may Mar. 1 at 2:32 PM
$HLXB get it to pennies
0 · Reply
dia_may
dia_may Mar. 1 at 2:32 PM
$HLXB tank
0 · Reply
dia_may
dia_may Mar. 1 at 2:31 PM
$HLXB tank this shit thank Irina & Steve Goss of Rockford, Michigan
0 · Reply
Jblack500
Jblack500 Feb. 28 at 6:58 PM
$HLXB $IBB $XBI $BBIO 11 watchers...early bird gets the worm
0 · Reply
Jblack500
Jblack500 Feb. 28 at 6:48 PM
$HLXB $VKTX $ABBY $BMY big news today in hlxb relating to bbio...get on board...bio is defensive when the market is volatile
0 · Reply
Jblack500
Jblack500 Feb. 28 at 6:34 PM
$BBIO $HLXB $SMMT $GILD well as things remain crazy in Washington biotech will act as a defensive play in a weak market.
0 · Reply
Jblack500
Jblack500 Feb. 28 at 3:52 PM
$HLXB $GILD $VKTX $SMMT bought 900 hlxb so far and added to smmt on goldman pt...over 100% upside https://www.fiercebiotech.com/biotech/bridgebios-kras-focused-cancer-spinout-backs-spac-path-nasdaq
0 · Reply
Jblack500
Jblack500 Feb. 28 at 3:10 PM
$BBIO $HLXB $EXEL $SMMT ended making a buy in bbio at 33.65...will buy more hlxb at 11 on the big news today, exel another 52 week high, and smmt rising more on goldman buy rating. Duggan will sell smmt for a big premium just like he did with Pharmacyclics
0 · Reply
RonIsWrong
RonIsWrong Feb. 28 at 2:52 PM
$HLXB
0 · Reply
RonIsWrong
RonIsWrong Feb. 28 at 2:51 PM
$HLXB $BBIO
1 · Reply
Jblack500
Jblack500 Feb. 28 at 2:24 PM
$BBIO $HLXB bbio 50 day ma is 32.23...I set a buy at 32.55
0 · Reply
Jblack500
Jblack500 Feb. 28 at 2:17 PM
$HLXB $VKTX $GILD $ABBV bought another 250 shares of hlxb on the big announcement with bbio...in for 750 now
0 · Reply
Jblack500
Jblack500 Feb. 28 at 2:06 PM
$BBIO $HLXB $GILD $SMMT I just bought 500 shares of hxlb on the huge bbio/hxlb news
1 · Reply
ActualSuperStableGenius
ActualSuperStableGenius Oct. 11 at 12:24 PM
$HLXB what is the story here. Why basically no activity
0 · Reply
IPOtweet
IPOtweet Jun. 13 at 8:37 PM
Back in SPACs: Experienced sponsors return to the SPAC market $HLXB $CCIXU $GPATU $PCSC $ALFUU $IPO #IPO https://zpr.io/faAqfUzyib5j
0 · Reply
JoshThe3rd
JoshThe3rd May. 17 at 9:09 PM
$HLXB Let's see what Chen has in store after MLTX ran from 5.00->60.00
0 · Reply